Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 και 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - Ανοσοκατασταλτικά - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ενδείκνυται για τη θεραπεία ενηλίκων ασθενών με μη προθεραπευμένο πολλαπλούν μυέλωμα που δεν είναι κατάλληλοι για μεταμόσχευση. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto - ρεπαγλινίδη - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - Η ρεπαγλινίδη ενδείκνυται σε ασθενείς με διαβήτη τύπου 2 (μη-ινσουλίνη - εξαρτώμενος διαβήτης mellitus (niddm)) των οποίων η υπεργλυκαιμία μπορεί πλέον να ελεγχθεί ικανοποιητικά με δίαιτα, μείωση βάρους και την άσκηση. Η θεραπεία πρέπει να αρχίζει ως πρόσθετο στη δίαιτα και την άσκηση προκειμένου να μειώσει τα επίπεδα γλυκόζης στο αίμα σε σχέση με τα γεύματα.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto - emtricitabine, tenofovir disoproxil succinate - hiv Λοιμώξεις - Αντιιικά για συστηματική χρήση - emtricitabine / tenofovir disoproxil krka d. ενδείκνυται σε αντιρετροϊκή θεραπεία συνδυασμού για τη θεραπεία ενηλίκων που έχουν μολυνθεί από hiv-1. emtricitabine / tenofovir disoproxil krka d. είναι, επίσης, ενδείκνυται για τη θεραπεία της λοίμωξης hiv-1 σε εφήβους, με nrti αντίσταση ή τοξικότητες αποκλείει τη χρήση της πρώτης γραμμής παράγοντες, ηλικίας 12 έως < 18 ετών.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

krka, d.d., novo mesto - οξική απιρατερόνη - Νεοπλάσματα του προστάτη - Ενδοκρινική θεραπεία - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - montelukast sodium - ΜΑΣΩΜΕΝΟ ΔΙΣΚΙΟ - 4mg/tab - ineof01106 montelukast sodium 4.160000 mg - montelukast

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - montelukast sodium - ΜΑΣΩΜΕΝΟ ΔΙΣΚΙΟ - 5mg/tab - ineof01106 montelukast sodium 5.200000 mg - montelukast

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia (0000005093) smarkeska cesta 6,, 8501 novo mest - montelukast sodium - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 10mg/tab - ineof01106 montelukast sodium 10.400000 mg - montelukast

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia smarkeska cesta 6,, 8501 novo mest 386 7 3312 233 - candesartan cilexetil; hydrochlorothiazide - tab (ΔΙΣΚΙΟ) - (8+12,5)mg/tab - candesartan cilexetil 8mg; hydrochlorothiazide 12,5mg - candesartan and diuretics